Inclusion Criteria:

1. No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or
Mitomycin C) prior to study initiation, and fully recovered from acute toxicities
associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.

2. Previously treated patients with a histology of refractory/relapsed indolent
lymphomas including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal
Marginal zone B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell
lymphoma (+/- villous lymphocytes).

3. Signed informed consent

4. Age >/= 18 years

5. Expected survival >/= 3 months

6. Pre-study Zubrod performance status of 0, 1, or 2

7. Acceptable hematologic status within two weeks prior to patient registration,
including: (a) Absolute neutrophil count ([segmented neutrophils + bands] * total
white blood count (WBC)) >/= 1,500/mm^3; (b) Platelet counts >/= 100,000/mm^3.

8. Female patients who are not pregnant or lactating

9. Men and women of reproductive potential who are following accepted birth control
methods (as determined by the treating physician)

10. Patients previously on Phase II drugs if no long-term toxicity is expected, and the
patient has been off the drug for eight or more weeks with no significant post
treatment toxicities observed

11. Patients determined to have < 25% bone marrow involvement with lymphoma within six
weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This
criteria must be strictly met for adequate patient safety.)

12. Patient should have at least one lesion measuring >/= 2 cm in a single dimension.

Exclusion Criteria:

1. Prior myeloablative therapies with autologous bone marrow transplantation (ABMT) or
peripheral blood stem cell (PBSC) rescue.

2. Platelet count< 100,000 cells/mm^3.

3. Presence of hypocellular bone marrow.

4. Patients with history of failed stem cell collection.

5. Prior radioimmunotherapy

6. Presence of Central Nervous System (CNS) lymphoma

7. Patients with HIV.

8. Patients with pleural effusion

9. Patients with abnormal liver function: total bilirubin > 2.0 mg/dL

10. Patients with abnormal renal function: serum creatinine > 2.0 mg/dL

11. Patients who have received prior external beam radiation therapy to > 25% of active
bone marrow (involved field or regional)

12. Patients who have received short-acting growth factor support (Leukine, Neupogen,
Procrit) within 2 weeks prior to treatment or long-acting growth-factor support
(Aranesp), Neulasta) within 4 weeks prior to treatment.

13. Serious nonmalignant disease or infection which, in the opinion of the investigator
and/or the sponsor, would compromise other protocol objectives

14. Major surgery, other than diagnostic surgery, within four weeks

15. Evidence of transformation in the latest biopsy